Short answer
Johnson & Johnson (JNJ) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Firefly acquisition completed and Sail strategic collaboration signed, marking expanded investment in biotech pipeline.
Johnson & Johnson 8-K event analysis
AI summary of each reported item and its exhibits
Item 7.01 · Regulation FD Disclosure
- Firefly acquisition completed and Sail strategic collaboration signed, marking expanded investment in biotech pipeline
- 2026 adjusted EPS guidance reduced $0.64 to $10.96–$11.11, with transactions cutting adjusted operational EPS by $0.64
- 2026 adjusted operational sales guidance maintained at 6.2%–6.8% growth, while reported sales midpoint reaches $101.1B
- Adjusted pre-tax operating margin outlook reduced approximately 150 basis points versus prior guidance
- 2027 adjusted EPS expected to decline approximately $1.36, largely from Sail’s potential milestone payments and option exercise
Item EX-99.1 · Exhibit EX-99.1
- Completed Firefly Bio acquisition for $1 billion cash, expanding J&J’s oncology platform into pan-KRAS and other difficult-to-treat cancers
- Firelink™ degrader antibody conjugate platform enables targeted protein degradation, supporting next-generation solid-tumor therapies
- Asset acquisition accounting triggers approximately $1 billion in-process R&D charge in Q3 2026
- Expected adjusted operational and adjusted EPS dilution of approximately $0.46 in 2026 and $0.08 in 2027
- Acquisition benefits remain dependent on clinical success, regulatory approval, commercialization, and integration execution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Johnson & Johnson 8-K filings
Get the next JNJ 8-K as it lands
Follow JNJ for push alerts, or ask the research agent what this filing means.